Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Alzheimer's disease virus-like particle-based vaccine - Novartis; Alzheimer's disease VLP-based vaccine - Novartis; Beta-amyloid protein immunotherapy - Novartis; CAD 106; Immunodrug™ for Alzheimer's disease - Novartis

Latest Information Update: 31 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cytos Biotechnology
  • Developer Cytos Biotechnology; Novartis
  • Class Alzheimer vaccines; Antidementias; Neuroprotectants; Virus-like particle vaccines
  • Mechanism of Action Amyloid beta-protein inhibitors; Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Alzheimer's disease
  • Discontinued Hypersensitivity; Rheumatoid arthritis

Most Recent Events

  • 15 Jul 2019 Discontinued - Phase-II/III for Alzheimer's disease in USA, Finland, Belgium, United Kingdom, Finland (IM)
  • 15 Feb 2017 Discontinued - Phase-II for Alzheimer's disease in European Union, USA, Switzerland (SC)
  • 13 Jun 2016 Phase-II/III clinical trials in Alzheimer's disease in Belgium and Finland (IM) (EudraCT2015-002715-15)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top